


Original Article
Cardiovascular Disorders



Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study

Hwanhee Park ^{1*}, Ki Wook Yun ^{2*}, Kyung-Ran Kim ¹, Seung Ha Song ², Bin Ahn ², Doo Ri Kim ¹, Gi Beom Kim ², June Huh ¹, Eun Hwa Choi ² and Yae-Jean Kim ¹

 OPEN ACCESS

Received: Jul 8, 2021

Accepted: Aug 3, 2021

Address for Correspondence:

Yae-Jean Kim, MD, PhD

Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea.

E-mail: yaejeankim@skku.edu

*Hwanhee Park and Ki Wook Yun contributed equally to this work.


© 2021 The Korean Academy of Medical Sciences.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs

Hwanhee Park 

<https://orcid.org/0000-0002-3337-408X>

Ki Wook Yun 

<https://orcid.org/0000-0002-0798-6779>

Kyung-Ran Kim 

<https://orcid.org/0000-0003-2557-3000>

Seung Ha Song 


<https://orcid.org/0000-0002-3453-7645>

Bin Ahn 

<https://orcid.org/0000-0002-3806-4275>

Doo Ri Kim 

<https://orcid.org/0000-0001-5233-4043>

Gi Beom Kim 

<https://orcid.org/0000-0002-7880-280X>

¹Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

²Department of Pediatrics, Seoul National University Children's Hospital, Seoul National University College of Medicine, Seoul, Korea

ABSTRACT


Background: Korean health authority plans to vaccinate adolescents against coronavirus disease 2019 (COVID-19) starting high school seniors during the summer vacation of 2021. However, the myocarditis/pericarditis following COVID-19 vaccine has been reported recently in adolescents and young adults. This study was performed to answer the urgent questions about the basic epidemiology and clinical course of myocarditis/pericarditis in hospitalized patients prior to the introduction of COVID-19 vaccines in pediatric population.

Methods: A retrospective medical record analysis including frequency, clinical characteristics, etiology and outcome of myocarditis/pericarditis was conducted in 17 years and younger patients who were hospitalized in two referral hospitals in Korea between 2010 and 2019.

Results: Total 142 patients with myocarditis (n = 119) and/or pericarditis (n = 23) were identified. Median age was 5.4 years (interquartile range, 0.6–12.9 years; range, 11 days–17.8 years), and male was 61%. In adolescents aged 12–17 years, the male to female ratio was 3.2. Myocarditis/pericarditis occurred 0.70 per 1,000 in-patients during the study period: 0.96 (< 1 year), 0.50 (1–5 years), 0.67 (6–11 years) and 1.22 (12–17 years) per 1,000 in-patients, respectively. There was an increasing tendency for the annual frequency from 0.34 in 2010 to 1.25 per 1,000 in-patients in 2019 (P = 0.021). Among the 56 (40%) proven pathogens at admission, *Mycoplasma pneumoniae* (n = 11, 8%) and enterovirus (n = 10, 7%) were most common. Of the 142 patients, 99 (70%) required pediatric intensive care unit care and 10 (7%) received heart transplantation. In addition, 61 patients (61/131, 47%) without heart medication at admission needed heart medication when they were discharged. Eleven (7.7%) patients died, of which five patients were previously healthy. The median age of deceased patients was lower than the survival group (0.8 vs. 6.3 years, P = 0.014).

Conclusion: The frequency of myocarditis/pericarditis was highest among male adolescent in-patients; however, the outcome was favorable in this group without any mortality.

Keywords: Myocarditis; Pericarditis; Epidemiology; COVID-19 Vaccines

June Huh <https://orcid.org/0000-0003-4523-9632>Eun Hwa Choi <https://orcid.org/0000-0002-5857-0749>Yae-Jean Kim <https://orcid.org/0000-0002-8367-3424>**Disclosure**

The authors have no potential conflicts of interest to disclose.

Author Contributions

Conceptualization: Kim YJ. Data curation: Park H, Song SH, Kim KR, Ahn B. Formal analysis: Park H, Kim KR, Yun KW. Methodology: Kim GB, Huh J. Investigation: Kim DR. Writing - original draft: Kim YJ, Park H, Yun KW. Writing - review & editing: Kim GB, Huh J, Choi EH, Kim YJ.

INTRODUCTION

Myocarditis/pericarditis are one of the most serious infectious and/or inflammatory diseases that can result from various etiology, most commonly viral infection,^{1,2} and can also be caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.³

Since the emergence of SARS-CoV-2 at the end of 2019, globally, there have been 181.9 million confirmed cases of coronavirus disease 2019 (COVID-19) and 3.9 million deaths as of June 30, 2021.⁴ COVID-19 vaccines were developed with an unprecedented speed in 2020, and as of June 30, 2021, 3.0 billion doses have been vaccinated with one of the emergently authorized vaccines.⁴ In South Korea, two viral vector vaccines (AZD1222 [AstraZeneca] and Ad26.COV2.S [Janssen]) and two mRNA vaccines (BNT162b2 [Pfizer-BioNTech] and mRNA-1273 [Moderna]) are authorized for emergency use.⁵ As of June 30, 2021, 18.8 million doses of vaccines were given, and 84,839 cases of adverse events were reported mainly for AZD1222 [AstraZeneca] and BNT162b2 [Pfizer-BioNTech] vaccines.⁶

Currently, BNT162b2 [Pfizer-BioNTech] vaccine is the only vaccine that has been authorized for use in adolescents 16 years and older in Korea and many other countries. In addition, on May 12, 2021, the U.S. Advisory Committee on Immunization Practices' (ACIP's) interim recommendations for the use of Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12–15 years were issued, and vaccination was performed in children to 12 years of age in the U.S.; 22.1% of adolescents ages 12–15 years has been fully vaccinated as of July 1, 2021.⁷ As of June 11, 2021, 4,229,597 doses were given in adolescents aged 12–17 years old and 147 cases of myocarditis/pericarditis were reported (19 cases from 2,189,726 doses given in female, 128 cases from 2,039,871 doses given in male assuming a 7-day post-vaccination observation window).⁸ It appears that the risk of developing myocarditis/pericarditis is higher after the second dose.

In Korea, COVID-19 vaccines have not been given to young individuals under the age of 18 years, but the Korean health authority plans to vaccinate adolescents starting high school seniors during the summer vacation of 2021.⁹ With this background, there is an urgent need for a review on the epidemiology and clinical manifestations of myocarditis/pericarditis among Korean children. We performed a retrospective study in patients who were hospitalized to two major hospitals in Korea due to myocarditis/pericarditis for 10 years before COVID-19 era.

METHODS

Study design and measures

A retrospective chart review was performed in pediatric patients aged 17 years and younger who were hospitalized in Samsung Medical Center (SMC), Sungkyunkwan University and Seoul National University Children's Hospital (SNUCH) from 2010 to 2019.

Patients who were hospitalized with myocarditis/pericarditis were identified with codes based on the National Center for Health Statistics International Classification of Diseases, 10th edition (ICD-10). Included codes were I40.0, I40.1, I40.8, I40.9, I41.0, I41.1, I41.2, I41.8, I51.4, I30.0, I30.1, I30.8, I30.9, I31.9, I32.0, and I32.1. Through the chart review, it was confirmed whether the diagnostic criteria for myocarditis/pericarditis such as chest pain,

elevated cardiac markers, and abnormal echocardiography were fulfilled.^{10,11} A patient who was admitted due to recurrent myocarditis/pericarditis was included only the first episode of myocarditis/pericarditis. In addition, a case of myocarditis/pericarditis in previously hospitalized patient was also enrolled in the study. Patients with chronic heart involvement with rheumatic heart disease, sarcoidosis, and autoimmune diseases and patients with cancer were excluded.

White blood cell (WBC) count, absolute neutrophil count, C-reactive protein (CRP), CK-MB, troponin I, troponin T, brain natriuretic peptide (BNP), or NT-pro BNP level, and ejection fraction on echocardiography were measured at the time of diagnosis. For etiology evaluation, results from culture, polymerase chain reactions, or serology obtained within three days of hospitalization were retrieved. For *Mycoplasma pneumoniae*, 1:640 or higher in the one-time gelatin particle immunoassay test was considered as positive.¹² Mortality rates in hospital-day 14 and 28, and overall in-hospital mortality were measured.

Statistical analysis

Statistical analysis was performed using the SPSS software version 27 (IBM Corp., Armonk, NY, USA). Categorical data were compared using the χ^2 test or the Fisher exact test. Continuous data were analyzed using the Mann-Whitney test. The frequency was calculated for year-specific, age-specific, and sex-specific analyses using the number of hospitalized patients by year and age at both hospitals except for cancer patients. Risk factors for fatal cases or poor outcome including ventilator or extracorporeal membrane oxygenation (ECMO) care, heart transplantation, and death were evaluated by multivariable logistic regression analysis. Variables with a *P* value of less than 0.1 in univariable analysis were chosen for multivariable analysis. The annual trends in frequency of myocarditis/pericarditis were conducted using the Cochran-Armitage's trend test. A *P* value < 0.05 was considered statistically significant.

Ethics statement

Institutional Review Board of Samsung Medical Center and Seoul National University Hospital (SNUH) were approved for this study respectively (approval No. 2021-06-141 by SMC and 2106-129-1228 by SNUH). Informed consent was waived because of the retrospective nature of the study.

RESULTS

Patient characteristics

Total 142 patients were identified, and patients' demographic information is shown in **Table 1**. The median age of all patients was 5.4 years (interquartile range [IQR], 0.6–12.9 years; range, 11 days–17.8 years). The median ages of male and female patients were 6.8 years (IQR, 1.1–14.1

Table 1. Patient demographics

Subjects and age by groups	Total (n = 142)	Male (n = 87, 61.3%)	Female (n = 55, 38.7%)	Ratio (male:female)	<i>P</i> value
Age, yr	5.4 (0.6–12.9)	6.8 (1.1–14.1)	3.9 (0.5–10.7)	1.6	0.05*
< 1 yr	39 (27)	22/87 (25)	17/55 (31)	1.3	0.121
1–5 yr	35 (25)	16/87 (18)	15/55 (27)	1.1	
6–11 yr	26 (18)	17/87 (20)	13/55 (24)	1.1	
12–17 yr	42 (30)	32/87 (37)	10/55 (18)	3.2	

Values are presented as median (interquartile range) or number (%).

*The value compared the differences between male and female.

years) and 3.9 years (IQR, 0.5–10.7 years), respectively. Male was 61% (n = 87) and male to female ratio was 3.2 in the adolescent group aged 12–17 years old. The proportions of patients in the age group 12–17 years were 30%, followed by 27% in a group < 1-year-old.

Frequency of myocarditis/pericarditis in hospitalized children

The frequency of myocarditis/pericarditis among 181,656 hospitalized patients excluding cancer patient were 0.08% during the study period: 0.78 per 1,000 in-patients. The frequencies in each age group were 0.96 per 1,000 in-patients (< 1 year), 0.50 per 1,000 in-patients (1–5 years), 0.67 per 1,000 in-patients (6–11 years) and 1.22 per 1,000 in-patients (12–17 years), respectively. Yearly frequency showed a significant increase in trends from 0.34 in 2010 to 1.25 per 1,000 in-patients in 2019 ($P = 0.021$) (Fig. 1).

Twenty-six percent of patients had underlying diseases and 11% had congenital heart diseases. It occurred throughout the year (Table 2).

Pathogens identified within 72 hours of hospitalization

In 85 patients (85/142, 60.0%), any pathogen was not identified. *M. pneumoniae* (n = 11) and enterovirus (n = 10) were the most common pathogens followed by rhinovirus (n = 7), adenovirus (n = 6), respiratory syncytial virus (n = 5), influenza virus (n = 4), parainfluenza virus (n = 3), and parvovirus (n = 2). Two or more pathogens were detected in each of three patients: adenovirus and endemic coronavirus, metapneumovirus and rhinovirus, and Epstein-Barr virus and *M. pneumoniae*, respectively.

Outcome and mortality

Of the 142 patients, 99 patients (99/142, 70%) required pediatric intensive care unit care, 56 patients (56/99, 57%) required ventilator care, and 27 patients (27/99, 27%) needed ECMO (Table 2). Eventually, 10 patients (10/142, 7%) received heart transplantation. Eight patients (8/142, 6%) needed pacemaker. One year after heart transplantation mortality was 10% (1/10 patients).




Fig. 1. The number of myocarditis/pericarditis patients per 1,000 in-patients from 2010 to 2019. The stippled bar shows the number of myocarditis/pericarditis patients per 1,000 in-patients in 0–17 years. Each line with red, blue, orange, and brown colors shows the number of patients per 1,000 in-patients in <1, 1–5, 6–11, 12–17 years, respectively. The most frequent age group is 12–17 years in almost years followed by group of under one year-old. The trend of total number of myocarditis/pericarditis increases over the years.

Table 2. Patient characteristics and comparison by outcomes

Characteristics	Total (n = 142)	Survived (n = 131)	Fatal (n = 11)	P value
Age ^a	5.4 (0.6 yr–12.9 yr, 11 days–17.8 yr)	6.3 (1.1 yr–13.6 yr, 11 days–17.8 yr)	0.8 (0.2 yr–0.3 yr, 14 days–12.4 yr)	0.014
Age by group				0.042
< 1 yr	39/142 (27)	33/131 (25)	6/11 (55)	
1–5 yr	35/142 (25)	32/131 (24)	3/11 (27)	
6–11 yr	26/142 (18)	24/131 (18)	2/11 (18)	
12–17 yr	42/142 (30)	42/131 (32)	0	
Male	87/142 (61)	82/131 (63)	5/11 (45)	0.337
Diagnosis				
Myocarditis	119/142 (83)	108/131 (82)	11/11 (100)	
Pericarditis	16/142 (11)	16/131 (12)	0	
Myocarditis and pericarditis	7/142 (5)	7/131 (5)	0	
Underlying disease	37/142 (26)	31/131 (24)	6/11 (54)	0.035
CHD	16/142 (11)	14/131 (11)	2/11 (18)	0.358
Seasonality				0.735
Mar–May	35 (25)	32 (24)	3 (27)	
Jun–Aug	31 (22)	30 (23)	1 (9)	
Sep–Nov	39 (28)	36 (28)	3 (27)	
Dec–Feb	37 (26)	33 (25)	4 (36)	
Laboratory findings ^b				
WBC, / μ L	10,235 (3,690–73,160)	10,290 (3,690–73,160)	10,180 (4,310–43,090)	0.439
ANC, / μ L	5,900 (560–49,896)	6,213 (560–49,896)	5,200 (1,030–19,820)	0.625
CRP, mg/dL	1.2 (0.1–41.5)	1.5 (0.1–38.4)	0.1 (0.1–41.5)	0.008
Troponin I, ng/mL	1.460 (0.006–180.970)	1.330 (0.006–180.970)	2.796 (0.050–29.432)	0.446
CK-MB, ng/mL	13.4 (0.2–1,604.5)	13.4 (0.2–1,604.5)	17.0 (0.0–149.0)	0.623
BNP, pg/mL	2,051 (10–31,168)	1,358 (10–31,168)	4,996 (2,129–13,795)	0.028
NT-proBNP, pg/mL	4,898.0 (9.9–36,874.0)	4,898.0 (9.9–36,874.0)	18,113.5 (395.0–35,000.0)	0.527
EF, M-mode (%)	49.0 (7.8–81.7)	51.6 (7.8–81.7)	26.2 (15.0–46.7)	0.004
Cases of ICU	99/142 (70)	88/131 (67)	11/11 (100)	0.034
Cases of ventilator	56/99 (57)	45/88 (51)	11/11 (100)	< 0.001
Cases of ECMO	27/99 (27)	21/88 (24)	6/11 (55)	0.007
Cases of heart transplantation	10/142 (7)	10/131 (8)	0	
Treatment				
IVIg	50/142 (35)	44/131 (34)	6/11 (55)	0.195
Methylprednisolone	28/142 (20)	24/131 (18)	4/11 (36)	0.227

Values are presented as median (^ainterquartile range and range or ^brange) or number (%).

Normal reference values: CRP (< 0.50 mg/dL), Troponin I (SMC: < 0.780 ng/mL, SNUCH: < 0.028 ng/mL), CK-MB (SMC: < 5.0 ng/mL, SNUCH: < 6.6 ng/mL), BNP (< 100 pg/mL), NT-proBNP (< 88.0 pg/mL).

CHD = congenital heart disease, WBC = white blood cell, ANC = absolute neutrophil count, CRP = C-reactive protein, BNP = brain natriuretic peptide, EF = ejection fraction, ICU = intensive care unit, ECMO = extracorporeal membrane oxygenation, IVIG = intravenous immunoglobulin.

When laboratory values were compared between survived patients and deceased patients, there were significant difference in CRP levels, BNP levels, and ejection fraction values (1.45 vs. 0.08 mg/dL, $P = 0.008$; 1,358 vs. 4,996 pg/mL, $P = 0.028$; 51.6% vs. 26.2%, $P = 0.004$) while WBC counts and other cardiac markers (Troponin I, CK-MB, and NT-pro-BNP) were comparable. All mortality cases and poor outcomes (ventilator, ECMO care, heart transplantation, and/or death) occurred in patients with myocarditis only.

For the patients with myocarditis only ($n = 119$), the univariable analysis showed that patients under 1 year old had poor outcomes ($P = 0.002$) (Table 3). However, no significant differences were found in poor outcomes according to the age of 12–17 years, gender, or presence of underlying disease. The multivariable analysis also showed that the age of under 1 year-old was the only independent risk factor for the poor outcomes in children with myocarditis ($P < 0.01$). We also performed multivariable analysis using the underlying disease and the age of less than 1 year with a P value of less than 0.1 among risk factors for fatal cases, but it was not statistically significant.

Table 3. Risk factors of poor outcomes according to univariable and multivariable analyses

Variables	No. (% ^a)	Univariable model		Multivariable model	
		Poor outcome (n = 59)		Poor outcome	
		No. (% ^b)	P value	aOR	95% CI
Age, < 1 yr ^c	37 (31.1)	26 (70.3)	0.002	3.643*	1.543–8.599
Age, 12–17 yr ^c	27 (22.7)	9 (33.3)	0.055	0.497	0.197–1.254
Sex, male	71 (59.7)	30 (42.3)	0.052	0.455	0.207–1.002
Underlying disease	34 (28.6)	21 (61.8)	0.093	1.938	0.819–4.584

The poor outcome group includes patients with ventilator, extracorporeal membrane oxygenation care, heart transplantation, and/or fatal cases.

aOR = adjusted odds ratio, CI = confidence interval.

^aProportion of patients with only myocarditis (n = 119) excluding pericarditis; ^bProportion of patients with the poor outcome by each variable; ^cMultivariable model was separately conducted for each age group.

*P < 0.01.

Among all patients, mortality occurred in 11 patients (11/142, 7.7%). Detailed information on their clinical features is described in **Table 4**. Six patients had underlying cardiologic or neurologic conditions (6/11, 55%). Of note, among five previously healthy children, two patients (SMC-32 and SMC-52) developed myocarditis due to infectious complications (one mycoplasma and one enterovirus), two patients (SNU-9 and SNU-12) expired due to dilated cardiomyopathy, and one patient (SNU-20) presented with cardiac arrest and the cause of cardiac arrest was not clear.

Among the survived patients, 61 patients (61/131, 47%) without any heart medication on admission required heart medication when they were discharged (**Fig. 2**).

DISCUSSION

This study investigated the epidemiology, clinical manifestations, and outcome on pediatric patients who were hospitalized due to myocarditis/pericarditis before the COVID-19 era. We observed that myocarditis/pericarditis occur in all ages with a predominance in the male adolescent age group 12–17 years and had favorable outcome without any mortality. In addition, an increasing tendency for the annual frequency of myocarditis/pericarditis was observed during the study period.

During the COVID-19 pandemic, the vaccine has been the most successful measurements to control the outbreak, in addition to social distancing policy. There was a dramatic decrease in




Fig. 2. The proportion of the survived patients with heart medication at discharge. Heart medications included digoxin, captopril, enalapril, carvedilol, furosemide, and spironolactone.

Table 4. Clinical characteristics of fatal cases

Patient ID	Sex	Age	Diagnosis	Underlying disease	Pathogen	Laboratory results			EF, %	Treatment		Intensive treatment		Mortality						
						WBC, / μ L	CRP, mg/dL	CK-MB, Troponin I, ng/mL		BNP, Pro-BNP, pg/mL	IVIG	Steroid	Admission to PICU	ECMO	Heart transplantation	14 days	28 days	In-hospital	Cause	
SMC-17	M	9 mon	Myocarditis	TOF	Unknown	21,280	0.03	9	2.37	NA	35,000	Severely decreased LV contractility	Yes	Yes	HD1	Yes	No	Yes	HD 23	TOF
SMC-31	M	9 yr	Myocarditis	Infantile SMA	Unknown	8,960	0.03	118	2.65	NA	395	NA	No	No	HD1	Yes	No	Yes	HD 2	Myocarditis
SMC-32	F	3 mon	Myocarditis	No	<i>M. pneumoniae</i>	9,550	0.10	3	7.85	NA	35,000	15	No	Yes	HD1	Yes	No	Yes	HD 31	Myocarditis
SMC-52	F	4 yr	Myocarditis	No	Enterovirus	43,090	0.08	54	29.43	NA	1,227	34	No	No	HD1	Yes	No	Yes	HD 28	Myocarditis
SNU-9	F	1 mon	Myocarditis	No	Unknown	4,310	0.15	1	0.59	4,996	NA	29	Yes	No	HD1	Yes	No	Yes	HD 50	DCMP
SNU-11	M	1 yr	Myocarditis	46, XY, del(7)(q31, 2q34)	Unknown	20,900	0.02	17	0.17	5,037	NA	26	No	No	HD1	Yes	No	Yes	HD 124	DCMP
SNU-12	M	4 mon	Myocarditis	No	Unknown	10,180	0.03	4	6.43	4,901	NA	24	Yes	No	HD1	Yes	No	Yes	HD 301	DCMP
SNU-16	F	20 days	Myocarditis	DORV	Unknown	19,950	0.35	126	17.13	2,129	NA	27	Yes	No	HD1	Yes	No	Yes	HD 31	DORV
SNU-20	M	14 days	Myocarditis	No	Unknown	15,430	0.55	0	NA	NA	NA	24	No	No	HD1	Yes	No	Yes	HD 7	Cardiac arrest
SNU-41	F	12 yr	Myocarditis	SMA	<i>S. aureus</i>	6,420	41.52	149	2.94	13,795	NA	47	Yes	Yes	HD1	Yes	No	Yes	HD 6	Septic shock
SNU-45	F	2 yr	Myocarditis	Prematurity	Unknown	9,700	0.08	33	0.05	NA	NA	26	Yes	Yes	HD 24	Yes	No	Yes	HD 52	DCMP

SMC = Samsung Medical Center, M = male, F = female, SNU = Seoul National University Children's Hospital, TOF = tetralogy of Fallot, SMA = spinal muscular atrophy, DORV = double outlet right ventricle, NA = not available, WBC = white blood cell, CRP = C-reactive protein, BNP = brain natriuretic peptide, EF = ejection fraction, LV = left ventricle, IVIG = intravenous immunoglobulin, PICU = pediatric intensive care unit, ECMO = extracorporeal membrane oxygenation, DCMP = dilated cardiomyopathy, HD = hospital day.

the burden of morbidity and mortality of COVID-19 in several countries where the COVID-19 vaccines were rolled out in the adult population early in 2020–2021. However, there have been changes in vaccine recommendation policies such as restricting ages or adding warnings after the reports on thrombosis with thrombocytopenia syndrome following adenovirus vectored COVID-19 vaccination in many countries.¹³⁻¹⁶ Although this raised concerns for vaccine safety issues and hesitancy, governments in all countries continued COVID-19 vaccination with careful monitoring for adverse events and assessment of the risks-and-benefit analysis. Following the adults, vaccination in the pediatric population has been the topic for discussion and debate.

After the rolling out the vaccines in adults in Korea, February 2021, COVID-19 vaccines have not been recommended to pediatric population yet as of the end of June 2021, Korea Disease Control and Prevention Agency plans to vaccinate high school seniors during the summer school break in July 2021. However, since the first report on seven adolescents who developed symptomatic acute myocarditis after the BNT162b2 [Pfizer-BioNTech] vaccines in the U.S.,¹⁷ post mRNA COVID-19 vaccination myocarditis has alerted the clinicians and health authorities.

Most of the COVID-19 infections in pediatric population showed mild symptoms and favorable clinical courses, but severe manifestations were observed in some patients with multisystem inflammatory syndrome in children (MIS-C). In the U.S., the cumulative incidence of MIS-C per 100,000 persons aged younger than 21 years was 2.1.¹⁸ On the other hand, as of June 11, 2021, the number of myocarditis/pericarditis reported per 1,000,000 doses of mRNA vaccines was 4.0,⁸ which is less common compared to the incidence of MIS-C. However, the incidence of MIS-C in Korea younger than 20 years is lower (only 3 cases were reported to the national surveillance system during seven months of surveillance period, 0.03 per 100,000 persons) than those in the U.S. or Europe.^{19,20} Moreover, safety issues have been concerned after the initiation of the mRNA vaccine to the pediatric population. The incidence by age should be considered because the incidence of myocarditis after mRNA vaccination was reported up to 66 cases per 1,000,000 doses in 12–17-year-old males.⁸ Therefore, the benefits and risks of vaccination and myocarditis/pericarditis should be considered while taking into account differences between region, race, and age.

Myocarditis often results from viral infections that have a predilection for the myocardium that causes unwanted immune-mediated inflammation and eventually myocardial cell dysfunction and reduced contractility.¹ Post-vaccination myocarditis is a known but rare adverse event after other vaccination, such as smallpox or diphtheria, whole-cell pertussis, and tetanus toxoid vaccination (DTP) vaccination.^{21,22} After smallpox vaccination, myocarditis occurred at a rate of 1 per 12,819 primary vaccinees (or 7.8 per 100,000 persons) among vaccinia naïve U.S. military personnel with mean age 26.5 (20–34 years). The time from vaccination to symptom onset was mean 10.5 days (range, 7–19 days), and all cases were white men.²¹ For myocarditis following DTP vaccination, there are only a few case reports, mainly after whole-cell pertussis vaccination, which is not used in Korea or other developed countries where acellular vaccines are used.

The baseline incidences of myocarditis may vary; In Korea, it has been reported to occur in 1.4 per 100,000 children in 2007 and 2.1 per 100,000 children in 2016 from a nationwide Health Insurance Review and Assessment Service Database (claims data of children and adolescents aged ≤ 19 years).²³ It was reported as 1.95 per 100,000 person-year in children < 15 years of age in Finland²⁴ and 2.16 expected cases per 100,000 U.S. military service members

in a 30-day period.²¹ Although population-level data from insurance claims may provide a big picture, further detailed data using hospital medical records would still be of interest to clinicians. In this study, data on children who were hospitalized to two major referral hospitals in Korea and present additionally useful and somewhat distinct observations.

In addition, the frequency of myocarditis showed to increase from 0.34 in 2010 to 1.25 in 2019 per 1,000 in-patients in this study. This trend is similar to other studies, and it was difficult to prove the exact cause in this study. However, other studies suggest that the increase in incidence is due to changes in physician's perception of the myocarditis²³ and the development of diagnostic techniques such as cardiac magnetic resonance imaging (MRI).²⁵

In a study by Kim and Cho,²³ they included only ICD-10 codes for I40, I41, or I51.4, while we included more codes as described in methods. In addition, Kim and Cho²³ combined the data for heart transplantation with deceased patients' data, but we combined the data for heart transplantation with survived patients' data since from clinician's standpoint, heart transplant recipients are still alive. Since we wanted to look at the baseline frequencies of myocarditis/pericarditis data in age groups in which the step-wise COVID-19 vaccination expansion is expected, our age group classification was further divided in children one year and older. The proportion of patients were 27% vs. 25% vs. 18% vs. 30% in four age groups (< 1 year vs. 1–5 years vs. 6–11 years vs. 12–17 years), respectively. It was also noted that in the age group 12–17 years, male predominance was observed. Kim and Cho²³ observed that nearly 50% of cases occurred between January and March, but our study did not show any significant seasonality.

The frequency of myocarditis showed a bimodal trend in infants and adolescents in this study, which was comparable to previous studies on pediatric myocarditis.^{25,26} In addition, age younger than one year was the risk factor for poor outcome in this present study with higher mortality than other age groups. A multicenter study in the U.S. reported that the death/transplant group had a lower median age than the survived group (7.75 years vs. 14 years).²⁶ Furthermore, a study using data from the Korean Health Insurance Review and Assessment Service, fulminant myocarditis showed the highest incidence in infants under 28 days, and the incidence decreased with increasing age.²³

The current study can present further data on discharge medication and detailed information on mortality cases. In addition, statistical analysis on laboratory data showed that there were differences in CRP level, BNP level, and ejection fraction value between the survival group and death group. Furthermore, age younger than 1 year and myocarditis without pericarditis were the main risk factor for the composite poor outcomes. These may serve as useful markers to predict the patient's course and outcome for clinicians in the early course of the disease, and this needs to be further confirmed in future studies.

In this study, the vaccination record was not reviewed in relation to myocarditis/pericarditis development, and biopsy or MRI was not performed in all patients to make the definite diagnosis of etiology. This study was performed in two tertiary centers in the capital area. Therefore, selection bias might have occurred. In addition, the evaluation of etiology was not made uniformly.

In conclusion, we observed that myocarditis/pericarditis occurred most commonly in young infants and adolescents with male predominance, particularly in adolescents. Unlike infants,

the outcome was fair in adolescents. Close monitoring for the occurrence of myocarditis/pericarditis is needed after the introduction of the COVID-19 vaccine to adolescents.

ACKNOWLEDGMENTS

We would like to express our gratitude to Joong Hyun Ahn for his advice on the statistical analysis of the data described in this manuscript.

REFERENCES

- Pollack A, Kontorovich AR, Fuster V, Dec GW. Viral myocarditis--diagnosis, treatment options, and current controversies. *Nat Rev Cardiol* 2015;12(11):670-80.
[PUBMED](#) | [CROSSREF](#)
- Fung G, Luo H, Qiu Y, Yang D, McManus B. Myocarditis. *Circ Res* 2016;118(3):496-514.
[PUBMED](#) | [CROSSREF](#)
- Basso C, Leone O, Rizzo S, De Gaspari M, van der Wal AC, Aubry MC, et al. Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. *Eur Heart J* 2020;41(39):3827-35.
[PUBMED](#) | [CROSSREF](#)
- World Health Organization. WHO coronavirus (COVID-19) dashboard. <https://covid19.who.int/>. Updated 2021. Accessed July 1, 2021.
- Kang HM, Choi EH, Kim YJ. Updates on the coronavirus disease 2019 vaccine and consideration in children. *Clin Exp Pediatr* 2021;64(7):328-38.
[PUBMED](#) | [CROSSREF](#)
- Korean Disease Control and Prevention Agency. Weekly COVID-19 vaccination adverse event (Week 17). <https://ncv.kdca.go.kr/board.es?mid=a11707010000&bid=0032#content>. Updated 2021. Accessed July 2, 2021.
- Centers for Disease Control and Prevention, COVID data tracker. <https://covid.cdc.gov/covid-data-tracker/#vaccinations-cases-trends>. Updated 2021. Accessed July 6 2021.
- Centers for Disease Control and Prevention. Advisory committee on immunization practices (ACIP), COVID-19 vaccine safety updates, June 23, 2021. <http://cdc.gov/coronavirus>. Updated 2021. Accessed July 6, 2021.
- Korean Disease Control and Prevention Agency. Press release, July 1 2021. http://ncov.mohw.go.kr/tcmBoardView.do?brdId=3&brdGubun=31&dataGubun=&ncvContSeq=5626&contSeq=5626&board_id=312&gubun=ALL. Updated 2021. Accessed July 2, 2021.
- Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J* 2013;34(33):2636-48.
[PUBMED](#) | [CROSSREF](#)
- Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. The 2015 ESC guidelines on the diagnosis and management of pericardial diseases. *Eur Heart J* 2015;36(42):2873-4.
[PUBMED](#) | [CROSSREF](#)
- Kim NH, Lee JA, Eun BW, Shin SH, Chung EH, Park KW, et al. Comparison of polymerase chain reaction and the indirect particle agglutination antibody test for the diagnosis of *Mycoplasma pneumoniae* pneumonia in children during two outbreaks. *Pediatr Infect Dis J* 2007;26(10):897-903.
[PUBMED](#) | [CROSSREF](#)
- Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. *N Engl J Med* 2021;384(22):2092-101.
[PUBMED](#) | [CROSSREF](#)
- Korean Disease Control and Prevention Agency. Press release, April 11, 2021. http://ncov.mohw.go.kr/tcmBoardView.do?brdId=3&brdGubun=31&dataGubun=&ncvContSeq=5156&contSeq=5156&board_id=312&gubun=BDJ. Updated 2021. Accessed July 2, 2021.
- Medicines and Healthcare products Regulatory Agency (UK). Press release, April 7, 2021. <https://www.gov.uk/government/news/mhra-issues-new-advice-concluding-a-possible-link-between-covid-19-vaccine-astazeneca-and-extremely-rare-unlikely-to-occur-blood-clots>. Updated 2021. Accessed July 2, 2021.

16. European Medicines Agency. AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets, April 7, 2021. <https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood>. Updated 2021. Accessed July 2, 2021.
17. Marshall M, Ferguson ID, Lewis P, Jaggi P, Gagliardo C, Collins JS, et al. Symptomatic acute myocarditis in seven adolescents following Pfizer-BioNTech COVID-19 vaccination. *Pediatrics*. Forthcoming 2021. DOI: 10.1542/peds.2021-052478.
[PUBMED](#) | [CROSSREF](#)
18. Belay ED, Abrams J, Oster ME, Giovanni J, Pierce T, Meng L, et al. Trends in geographic and temporal distribution of US children with multisystem inflammatory syndrome during the COVID-19 pandemic. *JAMA Pediatr* 2021;175(8):837-45.
[PUBMED](#) | [CROSSREF](#)
19. Choe YJ, Choi EH, Choi JW, Eun BW, Eun LY, Kim YJ, et al. Surveillance of COVID-19-associated multisystem inflammatory syndrome in children, South Korea. *Emerg Infect Dis* 2021;27(4):1196-200.
[PUBMED](#) | [CROSSREF](#)
20. Korean Statistical Information Service. 2019 Population census updated by the KOSIS. https://kosis.kr/statisticsList/statisticsListIndex.do?vwcd=MT_ZTITLE&menuId=M_01_01#content-group. Updated 2021. Accessed July 7, 2021.
21. Halsell JS, Riddle JR, Atwood JE, Gardner P, Shope R, Poland GA, et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. *JAMA* 2003;289(24):3283-9.
[PUBMED](#) | [CROSSREF](#)
22. Kumar V, Sidhu N, Roy S, Gaurav K. Myocarditis following diphtheria, whole-cell pertussis, and tetanus toxoid vaccination in a young infant. *Ann Pediatr Cardiol* 2018;11(2):224-6.
[PUBMED](#) | [CROSSREF](#)
23. Kim J, Cho MJ. Acute myocarditis in children: a 10-year nationwide study (2007–2016) based on the Health Insurance Review and Assessment Service Database in Korea. *Korean Circ J* 2020;50(11):1013-22.
[PUBMED](#) | [CROSSREF](#)
24. Arola A, Pikkarainen E, Sipilä JO, Pykärä J, Rautava P, Kytö V. Occurrence and features of childhood myocarditis: a nationwide study in Finland. *J Am Heart Assoc* 2017;6(11):e005306.
[PUBMED](#) | [CROSSREF](#)
25. Vasudeva R, Bhatt P, Lilje C, Desai P, Amponsah J, Umscheid J, et al. Trends in acute myocarditis related pediatric hospitalizations in the United States, 2007–2016. *Am J Cardiol* 2021;149:95-102.
[PUBMED](#) | [CROSSREF](#)
26. Butts RJ, Boyle GJ, Deshpande SR, Gambetta K, Knecht KR, Prada-Ruiz CA, et al. Characteristics of clinically diagnosed pediatric myocarditis in a contemporary multi-center cohort. *Pediatr Cardiol* 2017;38(6):1175-82.
[PUBMED](#) | [CROSSREF](#)